Patent intelligence · US
US 10857225
Smallpox vaccine for cancer treatment
Smallpox vaccine for cancer treatment
Patent details — US 10857225
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 8, 2020
- Expiration
- Dec 3, 2040
- Applicant
- Calidi Biotherapeutics, Inc.
- Claims
- 29
- CPC classes
- A61K, A61K2039/515, A61K2039/525, A61K2039/5254
Quick answer
US 10857225 (Smallpox vaccine for cancer treatment) is held by Calidi Biotherapeutics, Inc.. Status: granted. Granted Dec 8, 2020. Expires Dec 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Calidi Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K2039/515, A61K2039/525, A61K2039/5254, A61K2039/55, A61K2039/585
More from Calidi Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12036278
Smallpox vaccine for cancer treatment
granted -
US 11655455
Enhanced systems for cell-mediated oncolytic viral therapy
granted -
US 11607450
Smallpox vaccine for cancer treatment
granted -
US 11505782
Cell-based vehicles for potentiation of viral therapy
granted -
US 11285194
Combination immunotherapy approach for treatment of cancer
granted -
US 10105436
Smallpox vaccine for cancer treatment
granted
Frequently asked questions
What is US patent 10857225?
US 10857225 (Smallpox vaccine for cancer treatment) is held by Calidi Biotherapeutics, Inc.. Status: granted. Granted Dec 8, 2020. Expires Dec 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10857225?
Calidi Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 10857225 expire?
Our index shows an expiration date of Dec 3, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.